Related Experiment Videos
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma
George Wright1, Bruce Tan, Andreas Rosenwald
1Biometric Research Branch, Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Summary
This study developed a gene expression profiling method to classify diffuse large B cell lymphoma (DLBCL) into two distinct subgroups. These subgroups, germinal center B cell-like (GCB) and activated B cell-like (ABC) DLBCL, show significantly different survival rates.
Area of Science:
- Oncology
- Genomics
- Bioinformatics
Background:
- Accurate classification of cancer subtypes is crucial for effective treatment.
- Gene expression profiling offers a powerful tool for molecular subtyping of cancers.
- Diffuse Large B Cell Lymphoma (DLBCL) is a heterogeneous cancer with varying clinical outcomes.
Purpose of the Study:
- To develop and validate a statistical method for classifying cancer specimens based on gene expression profiles.
- To identify distinct molecular subgroups within Diffuse Large B Cell Lymphoma (DLBCL).
- To assess the clinical relevance of identified DLBCL subgroups regarding patient survival.
Main Methods:
- Utilized Bayes' rule for a statistical classification method to estimate subgroup membership probability.
- Applied the method to classify DLBCL biopsy samples using gene expression data from cDNA microarrays.
- Validated the classification predictor on a separate set of DLBCL biopsies profiled with oligonucleotide microarrays.
Main Results:
- Identified two distinct DLBCL subgroups: germinal center B cell-like (GCB) and activated B cell-like (ABC).
- GCB DLBCL expressed genes typical of normal germinal center B cells.
- ABC DLBCL expressed genes associated with plasma cells, including those for secretory proteins.
- The identified GCB and ABC subgroups showed significantly different 5-year survival rates (62% vs. 26%; P < 0.0051).
Conclusions:
- The gene expression-based predictor effectively classifies DLBCL into biologically and clinically distinct subgroups.
- The classification is robust and independent of the gene expression measurement method.
- This approach aids in understanding DLBCL heterogeneity and predicting patient outcomes.